RTB's analysis is substantially more detailed and
Post# of 148168
(Total Views: 673)
Posted On: 12/18/2020 8:34:24 PM
RTB's analysis is substantially more detailed and better informed than mine.
Suffice to say, until Cytodyn achieves revenue from sales, short term lending and dilution from sales will be necessary.
This may be for just a few more days or weeks.
The larger issue of the efficacy of leronlimab is trumps the rest. I believe, and have invested accordingly, that Leronlimab will reward us beyond most of our expectations.
Those who argue that the price will gap down to 3.40 or 3.16 are either completely uninformed, or more likely, trying to deceive you and others.
Have a great weekend.
Suffice to say, until Cytodyn achieves revenue from sales, short term lending and dilution from sales will be necessary.
This may be for just a few more days or weeks.
The larger issue of the efficacy of leronlimab is trumps the rest. I believe, and have invested accordingly, that Leronlimab will reward us beyond most of our expectations.
Those who argue that the price will gap down to 3.40 or 3.16 are either completely uninformed, or more likely, trying to deceive you and others.
Have a great weekend.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼